Article Text

PDF

Possible hepatotoxicity of IQOS
  1. Lauren Chun1,
  2. Farzad Moazed1,
  3. Michael Matthay1,2,3,
  4. Carolyn Calfee1,2,3,
  5. Jeffrey Gotts1
  1. 1 Department of Medicine, University of California, San Francisco, San Francisco, California, USA
  2. 2 Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California, USA
  3. 3 Department of Anesthesia, University of California, San Francisco, San Francisco, California, USA
  1. Correspondence to Dr Jeffrey Gotts, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; jeffrey.gotts{at}ucsf.edu

Statistics from Altmetric.com

On 25 January 2018, the Food and Drug Administration (FDA) Tobacco Scientific Advisory Committee unanimously voted (with one abstention) that Phillip Morris International (PMI) could not claim their heated tobacco product (HTP) IQOS (I-Quit-Ordinary-Smoking) would reduce the risk of tobacco-related diseases. Regardless, IQOS is already available in over 30 countries, and thus merits scrutiny from the scientific and medical communities. The preclinical and clinical data PMI submitted to FDA indicate that IQOS exposure may be associated with unexpected liver toxicity. We reviewed preclinical studies conducted by PMI scientists1 and clinical studies of 5 and 90 days of exposure to IQOS and IQOS menthol2–5 included in PMI’s Modified Risk Tobacco Product application submitted to the US FDA.

Wong and colleagues1 exposed 92 male and 92 female Sprague Dawley rats to up to 90 days of mainstream aerosol from IQOS, mainstream smoke from 3R4F research cigarettes, or room air (sham). After 90 days of exposure, liver weights and blood levels of alanine aminotransferase (ALT) were measured. ALT is an enzyme released into the blood by hepatocytes during hepatocellular injury6 and liver weight is a sensitive measure of hepatocellular hypertrophy.7 After 90 days, ALT levels and liver weights were significantly higher with IQOS than with conventional cigarettes in female animals (table 1). Hepatocellular vacuolisation, a sign of acute liver injury,7 was significantly increased in IQOS-exposed female rats, an effect not seen in cigarette-exposed animals (table 1).

Table 1

Liver parameters in Sprague Dawley rats after 90 days of exposure

The human clinical data PMI submitted to FDA provide further cause for concern. Increased plasma bilirubin may signify cholestatic liver injury with impaired hepatic bile flow, accelerated red blood cell destruction, or decreased bilirubin metabolism.7 Following 5 days of exposure to IQOS, conventional cigarettes or smoking abstinence, plasma bilirubin was elevated in 8.8% of IQOS subjects compared with 0% of cigarette smokers and 2.6% in abstainers.2 In another 5-day study, the mean increase in ALT was higher with IQOS than with conventional cigarettes or smoking abstinence (4.5, 2.9 and 1.6 IU/L, respectively).3 In a 90-day study of exposure to mentholated IQOS, mentholated cigarettes or smoking abstinence, the only subject experiencing a grade 2 (moderate) increase in ALT was in the IQOS group.4 In another study, the rate of grade 1 (mild) increases in ALT after 60 days of exposure was highest with IQOS at 6.3% compared with 0% for conventional cigarettes and 2.6% with smoking abstinence.5

Hepatotoxicity constitutes a broad spectrum of injuries to the liver, with consequences ranging from asymptomatic lab abnormalities to hepatic failure and death.6 7 Notably, there is some evidence that smoking cessation may be associated with a small increase in the unconjugated fraction of bilirubin over the next 1–4 weeks, averaging 0.06 mg/dL.8 However, in the 5-day exposure study cited above, the rate of elevated bilirubin (>1.0 mg/dL) in IQOS users was over three times higher than that observed with smoking abstinence (8.8% vs 2.6%), and the mean increase above baseline was 0.05 mg/dL with IQOS compared with −0.07 mg/dL with smoking abstinence.2 We can find no evidence in the literature that smoking cessation is associated with an increase in ALT.

Taken together, PMI’s preclinical and clinical data constitute a concerning pattern of possible hepatotoxicity, especially considering the short period of exposure. These findings indicate IQOS may have unexpected organ toxicity that has not been associated with cigarettes. Although IQOS exposes users to lower levels of many toxins than conventional cigarettes, it exposes users to higher levels of other toxins (St Helen et al, submitted manuscript). Given the potential for synergistic hepatotoxicity with other medications (eg, acetaminophen), alcohol9 10 and herbal supplements, the public health community should focus intense scrutiny on possible liver injury in users of IQOS and other HTPs. A broader implication of this finding is that health assessments of IQOS and other non-cigarette tobacco products should consider possible toxicities not associated with conventional cigarettes.

References

View Abstract

Footnotes

  • Contributors LC, FM, CC, MM and JG drafted the manuscript. LC, FM, CC, MM and JG edited and revised the manuscript. LC, FM, CC, MM and JG prepared the tables. LC, FM, CC, MM and JG approved the final version of the manuscript.

  • Funding This study was funded by the National Institutes of Health (Grant No 1P50-CA-180890) and the Center for Tobacco Products (Grant No 1P50-CA-180890).

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.